Effects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4317716)

Published in Nephrourol Mon on July 05, 2014

Authors

Mostafa Sharifian1, Banafsheh Arad1, Naser Simfroosh1, Abbas Basiri1, Hassan Otukesh2, Nasrin Esfandiar1

Author Affiliations

1: Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
2: Iran University of Medical Sciences, Tehran, IR Iran.

Articles cited by this

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med (1998) 3.76

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 1.88

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58

Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant (2004) 1.26

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation (1999) 1.24

Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation (2001) 1.19

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ (2003) 1.12

Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant (2007) 1.12

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 1.09

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation (2003) 0.97

Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs (2003) 0.96

Basiliximab induction in renal transplantation: long-term outcome. Saudi J Kidney Dis Transpl (2013) 0.88

High incidence of bacteriuria following renal transplantation in children. Nephrol Dial Transplant (1998) 0.87

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation (2002) 0.86

Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol (2003) 0.84

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant (2002) 0.83

The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologics (2008) 0.78

Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs (2004) 0.77

Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab. Transplant Proc (2001) 0.77